Want to see GB:OXB full AI Analyst Report?
Oxford BioMedica (OXB) Ratios
Oxford BioMedica Ratios
GB:OXB's free cash flow for Q2 2026 was $-25.24M. For the 2026 fiscal year, GB:OXB's free cash flow was decreased by $-6.89M and operating cash flow was $-18.35M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.20 | 2.28 | 3.19 | 3.61 | 4.92 |
| Quick Ratio | 2.00 | 2.05 | 2.90 | 3.40 | 4.63 |
| Cash Ratio | 1.15 | 1.04 | 2.34 | 2.37 | 3.27 |
| Solvency Ratio | -0.04 | -0.12 | -0.74 | -0.06 | 0.63 |
| Operating Cash Flow Ratio | -0.06 | -0.87 | -0.64 | -0.21 | 0.76 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -180.17 | -7.80 | -3.83 | 29.84 |
| Net Current Asset Value | $ -48.73M | $ -37.96M | $ -33.18M | $ -8.48M | $ 113.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.45 | 0.47 | 0.44 | 0.25 | 0.04 |
| Debt-to-Equity Ratio | 1.62 | 1.91 | 1.51 | 0.56 | 0.05 |
| Debt-to-Capital Ratio | 0.62 | 0.66 | 0.60 | 0.36 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.31 | 0.41 | 0.34 | 0.16 | 0.00 |
| Financial Leverage Ratio | 3.57 | 4.06 | 3.41 | 2.25 | 1.27 |
| Debt Service Coverage Ratio | -0.56 | -1.55 | -9.71 | -0.83 | 18.58 |
| Interest Coverage Ratio | -2.14 | -4.00 | -16.45 | -3.45 | 23.39 |
| Debt to Market Cap | 0.06 | 0.09 | 0.20 | 0.10 | 0.00 |
| Interest Debt Per Share | 1.45 | 1.15 | 1.27 | 1.30 | 0.12 |
| Net Debt to EBITDA | -5.62 | -3.36 | -0.05 | 2.50 | -3.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 39.10% | 41.17% | 44.37% | 49.42% | 57.87% |
| EBIT Margin | -17.55% | -29.06% | -198.05% | -26.59% | 14.54% |
| EBITDA Margin | -5.41% | -11.13% | -165.98% | -7.71% | 23.27% |
| Operating Profit Margin | -17.55% | -30.57% | -205.69% | -21.59% | 14.54% |
| Pretax Profit Margin | -18.93% | -36.70% | -210.55% | -32.84% | 13.92% |
| Net Profit Margin | -17.85% | -33.53% | -175.89% | -27.97% | 13.31% |
| Continuous Operations Profit Margin | -18.16% | -37.74% | -205.68% | -32.26% | 13.31% |
| Net Income Per EBT | 94.34% | 91.38% | 83.54% | 85.17% | 95.63% |
| EBT Per EBIT | 107.86% | 120.04% | 102.36% | 152.14% | 95.72% |
| Return on Assets (ROA) | -9.25% | -18.65% | -62.41% | -8.51% | 8.01% |
| Return on Equity (ROE) | -32.98% | -75.71% | -212.81% | -19.13% | 10.15% |
| Return on Capital Employed (ROCE) | -12.26% | -22.72% | -88.53% | -7.55% | 10.18% |
| Return on Invested Capital (ROIC) | -11.48% | -22.15% | -83.55% | -7.29% | 9.66% |
| Return on Tangible Assets | -10.02% | -21.34% | -71.15% | -11.05% | 8.02% |
| Earnings Yield | -4.36% | -9.94% | -74.14% | -9.33% | 1.85% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.59 | 3.06 | 6.71 | 2.43 | 3.39 |
| Payables Turnover | 7.23 | 7.88 | 8.23 | 5.20 | 11.44 |
| Inventory Turnover | 5.93 | 5.58 | 3.87 | 5.61 | 6.32 |
| Fixed Asset Turnover | 1.57 | 2.00 | 1.18 | 1.05 | 2.05 |
| Asset Turnover | 0.52 | 0.56 | 0.35 | 0.30 | 0.60 |
| Working Capital Turnover Ratio | 1.91 | 1.50 | 0.71 | 0.98 | 1.54 |
| Cash Conversion Cycle | 152.07 | 138.42 | 104.36 | 145.12 | 133.45 |
| Days of Sales Outstanding | 140.98 | 119.34 | 54.39 | 150.17 | 107.60 |
| Days of Inventory Outstanding | 61.55 | 65.38 | 94.32 | 65.08 | 57.77 |
| Days of Payables Outstanding | 50.47 | 46.30 | 44.35 | 70.13 | 31.91 |
| Operating Cycle | 202.54 | 184.72 | 148.71 | 215.25 | 165.37 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.05 | -0.49 | -0.30 | -0.13 | 0.30 |
| Free Cash Flow Per Share | -0.09 | -0.56 | -0.40 | -0.30 | 0.19 |
| Dividend Paid and CapEx Coverage Ratio | -1.15 | -6.75 | -2.90 | -0.77 | 2.69 |
| Capital Expenditure Coverage Ratio | -1.15 | -6.75 | -2.90 | -0.77 | 2.69 |
| Operating Cash Flow Coverage Ratio | -0.04 | -0.47 | -0.26 | -0.11 | 2.73 |
| Operating Cash Flow to Sales Ratio | -0.03 | -0.39 | -0.32 | -0.09 | 0.18 |
| Free Cash Flow Yield | -1.48% | -13.38% | -18.05% | -6.89% | 1.56% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -22.85 | -10.00 | -1.35 | -10.72 | 54.01 |
| Price-to-Sales (P/S) Ratio | 4.09 | 3.37 | 2.37 | 3.00 | 7.19 |
| Price-to-Book (P/B) Ratio | 7.56 | 7.62 | 2.87 | 2.05 | 5.48 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -67.62 | -7.48 | -5.54 | -14.51 | 64.20 |
| Price-to-Operating Cash Flow Ratio | -126.66 | -8.58 | -7.45 | -33.26 | 40.34 |
| Price-to-Earnings Growth (PEG) Ratio | 0.64 | 0.13 | -0.00 | 0.04 | -0.14 |
| Enterprise Value Multiple | -81.33 | -33.67 | -1.48 | -36.36 | 27.91 |
| Enterprise Value | 741.80M | 482.64M | 220.16M | 392.62M | 927.25M |
| EV to EBITDA | -81.33 | -33.67 | -1.48 | -36.36 | 27.91 |
| EV to Sales | 4.40 | 3.75 | 2.46 | 2.80 | 6.49 |
| EV to Free Cash Flow | -72.63 | -8.30 | -5.74 | -13.58 | 57.98 |
| EV to Operating Cash Flow | -136.06 | -9.53 | -7.72 | -31.12 | 36.43 |
| Tangible Book Value Per Share | 0.59 | 0.30 | 0.49 | 1.37 | 2.24 |
| Shareholders’ Equity Per Share | 0.82 | 0.55 | 0.77 | 2.16 | 2.24 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.04 | -0.03 | 0.02 | 0.02 | 0.04 |
| Revenue Per Share | 1.51 | 1.24 | 0.93 | 1.48 | 1.71 |
| Net Income Per Share | -0.27 | -0.42 | -1.63 | -0.41 | 0.23 |
| Tax Burden | 0.94 | 0.91 | 0.84 | 0.85 | 0.96 |
| Interest Burden | 1.08 | 1.26 | 1.06 | 1.24 | 0.96 |
| Research & Development to Revenue | 0.37 | 0.04 | 0.66 | 0.44 | 0.28 |
| SG&A to Revenue | 0.22 | 0.23 | 0.28 | 0.20 | 0.11 |
| Stock-Based Compensation to Revenue | 0.03 | 0.00 | 0.04 | 0.05 | 0.03 |
| Income Quality | 0.18 | 1.07 | 0.18 | 0.27 | 1.28 |
Currency in GBP
